HC Wainwright Reiterates “Buy” Rating for Innate Pharma (NASDAQ:IPHA)

HC Wainwright reissued their buy rating on shares of Innate Pharma (NASDAQ:IPHA) in a report released on Monday morning,Benzinga reports. They currently have a $11.50 target price on the stock.

Separately, Evercore ISI upgraded Innate Pharma to a “strong-buy” rating in a research note on Monday, September 16th.

Innate Pharma Price Performance

IPHA opened at $1.90 on Monday. The business’s fifty day moving average is $1.80 and its 200-day moving average is $2.11. Innate Pharma has a 52-week low of $1.29 and a 52-week high of $3.15.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.